Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-682-0645
Debt
Current Ratio13.11
Quick Ratio12.95
Price-To-Earnings
Sales & Book Value
Annual Sales$7.20 million
Price / Sales9.17
Price / Cash FlowN/A
Price / Book0.47
Profitability
Net Income$-51,860,000.00
Net Margins-2,409.84%
Return on Assets-40.33%
Miscellaneous
Employees56
OptionableOptionable
Immune Design (NASDAQ:IMDZ) Frequently Asked Questions
What is Immune Design's stock symbol?
Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."
How were Immune Design's earnings last quarter?
Immune Design Corp (NASDAQ:IMDZ) announced its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.03. The biotechnology company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.75 million. Immune Design had a negative return on equity of 43.44% and a negative net margin of 2,409.84%. View Immune Design's Earnings History.
When is Immune Design's next earnings date?
What price target have analysts set for IMDZ?
4 Wall Street analysts have issued 12 month price objectives for Immune Design's shares. Their predictions range from $8.00 to $11.00. On average, they anticipate Immune Design's stock price to reach $9.00 in the next year. This suggests a possible upside of 556.9% from the stock's current price. View Analyst Price Targets for Immune Design.
What is the consensus analysts' recommendation for Immune Design?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immune Design in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immune Design.
What are Wall Street analysts saying about Immune Design stock?
Here are some recent quotes from research analysts about Immune Design stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential contribution from pipeline development. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (1/14/2019)
- 2. According to Zacks Investment Research, "Immune Design’s primary candidate, G100 is being developed for merkel cell carcinoma, follicular non-Hodgkin Lymphoma and sarcoma. The company’s initial focus is to assess the efficacy of G100 combined with Merck’s Keytruda in relapsed refractory follicular lymphoma patients who have received three prior lines of systemic therapy. The company’s strategic agreements with companies like Sanofi, Roche and Merck is positive as it not only validate its GLAAS platform but also provide the company with funds in the form of collaboration and license revenues. Although such collaborations boost its pipeline development, heavy dependence on other companies for revenue growth increases the company’s vulnerability. However, in October 2018, Immune Design discontinued CMB305 cancer vaccine program, following a review of its portfolio. Shares of the company underperformed the industry year to date." (1/8/2019)
Has Immune Design been receiving favorable news coverage?
News stories about IMDZ stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Immune Design earned a news impact score of 0.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Immune Design's key competitors?
Some companies that are related to Immune Design include Verastem (VSTM), Savara (SVRA), Kadmon (KDMN), Intec Pharma (NTEC), Tyme Technologies (TYME), Marker Therapeutics (MRKR), Catalyst Pharmaceuticals (CPRX), Urovant Sciences (UROV), Seres Therapeutics (MCRB), Avid Bioservices (CDMO), Adamas Pharmaceuticals (ADMS), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Strongbridge Biopharma (SBBP) and Acer Therapeutics (ACER).
Who are Immune Design's key executives?
Immune Design's management team includes the folowing people:
- Dr. Carlos V. Paya, CEO, Pres & Director (Age 59)
- Mr. Stephen R. Brady, Exec. VP of Strategy & Fin. (Age 48)
- Dr. Jan Henrik Ter Meulen, Chief Scientific Officer (Age 55)
- Sylvia Wheeler, Investor Relations Officer
- Dr. Wayne R. Gombotz, Chief Devel. Officer (Age 59)
How do I buy shares of Immune Design?
Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Design's stock price today?
One share of IMDZ stock can currently be purchased for approximately $1.37.
How big of a company is Immune Design?
Immune Design has a market capitalization of $69.84 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.
What is Immune Design's official website?
How can I contact Immune Design?
Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]
MarketBeat Community Rating for Immune Design (NASDAQ IMDZ)
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
